Introduction: Human immunodeficiency virus (HIV)-associated lipodystrophy syndrome (LS) is defined as a redistribution of adipose tissue, metabolic and endocrine abnormalities, resulting from combined antiretroviral therapy (cART). Aim of this study was to evaluate LS in HIV-infected patients from Lower Silesia, Poland.
Introduction
Human immunodeficiency virus (HIV)-associated lipodystrophy syndrome (LS) is defined as a redistribution of adipose tissue accompanied by metabolic and endocrine abnormalities, resulting from combined antiretroviral therapy (cART) [1] [2] [3] [4] [5] .
The term was first used in 1998 by Andrew Carr et al. to describe morphological and metabolic abnormalities observed in HIV-infected patients treated with protease inhibitors (PIs) [2] . However, further studies also discovered the influence of other antiretroviral drugs, mostly nucleoside reverse transcriptase inhibitors (NRTIs), and of HIV infection itself [6] [7] [8] [9] [10] [11] . Most authors emphasize the significant role of adipose tissue in pathogenesis of this condition; the role of the immune system, proinflammatory cytokines such as TNF-α and interleukin (IL)-6 and genetic predisposition are also mentioned [2, 3, 8, 12, 13] .
The morphological abnormalities observed in clinical presentation of patients with LS include: lipoatrophy (loss of subcutaneous adipose tissue in the face, limbs, and buttocks), isolated or accompanied by lipoaccumulation (growth of adipose tissue in the abdomen, waist, neck and growth of visceral adipose tissue) [14] [15] [16] [17] [18] [19] .
Lipoatrophy should be distinguished from cachexia and malnutrition observed in advanced stages of AIDS and chronic infections accompanying HIV infection. Therapy with PI is considered by many authors as an independent risk factor for the development of insulin resistance, abnormal glucose tolerance and diabetes mellitus type 2 [20] [21] [22] [23] [24] . Other metabolic abnormalities include: increased triglyceride concentration, low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) cholesterol and apolipoproteins B and E levels, lower high-density lipoprotein (HDL) cholesterol level [25] [26] [27] .
The aim of this study was to evaluate the lipodystrophy syndrome in HIV-infected patients living in Lower Silesia, Poland.
Material and methods

Material
One hundred and ten HIV-infected patients, treated in the Acquired Immunodeficiency Syndrome Outpatient Clinic in Wroclaw were included in the observational study. The same study population was analyzed in our previous publications [28] . The preliminary inclusion criteria were: documented HIV infection and antiretroviral therapy, of no less than 2 years. The exclusion criteria were: AIDS diagnosis, acute medical condition (fever, severe infection, inflammation), serum creatinine level over 2 mg% and over fivefold increase in the alanine aminotransferase level, body mass index (BMI) > 30 kg/m 2 , age over 65 years old, diabetes, treatment with such drugs as metphormin. The following patient data were known at the beginning of the study: current virological and immune status, history of the infection and information about coinfection with hepatitis B and/or hepatitis C virus (Table 1) .
All patients were on antiretroviral treatment for 2-8 years, 4 years on average. The time of cumulative antiretroviral treatment with medications from all antiretroviral classes was from about 8 to 25 years, 16.6 years on average; the longest cumulative time of treatment concerned NRTI. We did not analyze contribution of certain antiretroviral drugs and their classes in the LS. Before the beginning of this study there were changes in the cART in many patients because of drug toxicity and viral failure.
The control group included 42 healthy individuals living in Lower Silesia, matched for age and sex with the patients, with negative medical history of chronic diseases and cardiovascular disease events ( Table 2) .
Characteristics of the study group (SG) and control group (CG) are presented in Table 2 .
Methods
The study protocol included collecting anamnesis and data from medical documentation, especially information about HIV infection and antiretroviral treatment (in years and cumulative treatment with NNRTI, NRTI, PI). Physical examination was performed with particular emphasis on anthropometric measurements -weight, height, waist and hip circumferences, BMI and waist-hip ratio (WHR). The evaluation of clinical features of LS was carried out using the methodology of HIV Outpatient Study (HOPS), a multi-site clinical study of over 4800 patients receiving ambulatory care in the USA in 1992-1998 [18] . The LS features were evaluated by two physicians -researchers, taking into consideration patients' opinions. The physical examination included evaluation of upper and lower limbs, buttocks, hips and face regarding fat loss and of visceral regions, trunk and neck with regard to fat accumulation. The researchers graded all the changes from 0 points (absent) to 3 points (the most severe). The maximum possible score was 15 points.
The quantitative parameter for lipodystrophy was used for analyzing dependencies between lipodystrophy and atherosclerosis. All changes were classified in a four-degree scale reflecting the severity of lipodystrophy syndrome: no LS symptoms, subtle changes -noticeable only if specifically looked for, with no change in clothing fit (up to 3 points), moderate changes -easily noted by the patient or physician, often requiring a change in clothing size (3-7 points), severe changes obvious to the casual observer, requiring a change in clothing size (over 7 points) ( Figure 1 ).
Following the HOPS method, two main subgroups of patients were established: 1) patients with no or slight symptoms of lipodystrophy (57 individuals) -LS1, 2) patients with moderate and severe changes (53 individuals) -LS2.
The purpose of this division was to compare their virological, immunological and clinical state and to evaluate the data concerning cART in both subgroups. The patients were also divided according to the type of lipodystrophic changes, into the following subgroups: lipoatrophy (n = 34), lipoaccumulation (n = 14), mixed forms -features of both lipoatrophic and lipohypertrophic changes (n = 46). In the control group, no features of lipoatrophic or mixed lipodystrophic changes were observed; 15 controls had symptoms of visceral obesity.
In all patients, a duplex ultrasound of carotid was performed in order to evaluate subclinical atherosclerosis by means of computer-measured cIMT. Carotid ultrasound was performed using a high-resolution ultrasound GE LOGIQ 7 GE with broadband linear probe 6-12 MHz. The main parameters for each patient were cIMT (the average IMT value obtained for all the series) and IMT meanmax (defined as the average of 12 maximal IMT measurements from each projection) [29] .
Statistical analysis
Quantitative variables were presented as an arithmetic mean, geometric mean or median, depending on normality of distribution. To achieve normality, the logarithmic transform was applied to the variable elements. For each estimator, 95% confidence intervals were calculated. Qualitative variables are presented as the number of patients in each group. Differences in quantitative features between groups were analyzed by Student's t-test, the Mann-Whitney test or Kruskal-Wallis wit post-hoc analysis. Differences in the qualitative features were analyzed using the χ 2 test or Fisher's exact test (for small groups). The effect of clinical features on lipodystrophy was assessed using logistic regression. The analysis was made using R and MedCalc statistical packages. All results with a significance level p < 0.05 were found significant.
The study was conducted with the approval of the Bioethics Committee. All participants provided their written informed consent to participate in the study, according to the Helsinki Declaration.
Results
At the beginning of the study, the patients were classified according to the severity of lipodystrophy syndrome, from no LS symptoms to severe changes in adipose tissue distribution. The subgroups with subtle and moderate changes were the most numerous ( Figure 1 ). Table 3 presents and compares the characteristics of both subgroups. The patients from LS2 subgroup were significantly older, had much lower body weight and smaller hip circumference and, as a result, lower WHR.
Patients from LS2 subgroup had noticeably more advanced atherosclerotic changes, expressed by higher cIMT values. Both LS1 and LS2 patients had significantly higher IMT mean-max values in comparison with the control group. Among traditional risk factors, there was a noticeable difference concerning smoking. Patients with advanced lipo dystrophy syndrome had very high pack-year values. After further post-hoc analysis of subgroups and the control group, it was discovered that LS1 had hypertension much more frequently than controls (0.033). In comparison with the control group, LS2 had significantly lower LDL cholesterol and higher triglyceride values (p = 0.015, p = 0.028 respectively). No other statistically significant differences in basic laboratory parameters or concerning cardiovascular disease risk factors were observed (Table 3) .
Patients in LS2 subgroup had noticeably longer documented time of HIV infection (Table 4) . General time of cART and cumulative time on antiretroviral drugs, including cumulative time on PIs and cumulative time on NRTIs, were significantly longer in LS2. Some interesting findings of little statistical significance indicate a higher current CD4+ T-lymphocyte count and more frequent HCV infection in patients with more severe adipose tissue changes.
Various combinations of fat distribution abnormalities were observed in LS patients. The most common one was cumulative fat loss in areas of the face, limbs, waist and hips (lipo atrophy); another frequent pattern was lipoatrophy combined with lipoaccumulation in the visceral area (mixed lipodystrophy). The percentages of particular combinations are presented in Figure 2 .
Within the whole group, all types of dystrophic changes were observed: lipoatrophy (30.9%), lipoaccumulation (12.7%) and, most frequently, mixed forms (41.7%). Figure 3 shows numbers of patients in specific subgroups, according to various dystrophic changes. Table 5 presents statistically significant differences observed in patients with different types of lipodystrophy. There were significant differences between the subgroups, concerning anthropometric measurements: BMI and waist circumference were noticeably higher in lipoaccumulation and mixed subgroups than in the lipoatrophy group; hip circumference was significantly lower in the atrophy In further analysis of logistic regression cumulative cART and smoking had an influence on the severity of lipodystrophy syndrome (Table 6) . In subsequent models, after disregarding cumulative cART and including cumulative NRTIs and PIs treatment, and then NNRTIs treatment, it was discovered that cumulative NRTIs treatment and smoking had an independent influence on severity of lipodystrophy syndrome (p = 0.004 and p = 0.0152, respectively) ( Table 6 ). Adding the current number of CD4+ T-lymphocytes to the model did not change the result and had no impact on the severity of LS.
*Median, IQR, n (%) -absolute number (percentage), other data -arithmetic mean HET -heterosexual contacts, IDU -intravenous drug users, MSM -men who have sex with men
Discussion
Prevalence of LS in HIV-infected patients varies from 8% to 84% in different studies; it is usually correlated to the characteristics of the research project, inclusion criteria and observation time [1, 10, 18, 19, 22, [30] [31] [32] .
In this study, 94 out of 110 patients were diagnosed with LS, which represents 85% of the study group. This is not an isolated case of such a high percentage of LS diagnosis. Similar results were observed by Rozenbaum et al. (84%) and by Carr et al. (83%) [14, 19] .
However, some studies indicate a much lower prevalence of LS, e.g. Martinez et al. diagnosed it in 17% of patients, Mercie et al. -in 26% of patients [25, 27] .
All types of dystrophic changes were observed in our study, with the majority of mixed forms (41.7%), lipoatrophy (30.9%) and, least frequently, lipoaccumulation (12.7%). These results are consistent with the findings of the HIV Outpatient Study, where LS was diagnosed in 49% of patients, mixed forms were most frequent (22.7%) and prevalence of lipoatrophy (13.3%) and lipoaccumulation (13.2%) were similar [18] . Different findings were presented by Thiebaut et al. in a French cohort, where mixed forms were least Table 5 . Statistically significant differences in subgroups depending on LS type In the presented cohort, significant differences in anthropometric measurements were observed, depending on the type and severity of LS. Patients with more advanced LS had lower BMI and higher WHR. The higher WHR was a consequence of a significantly lower hip circumference, resulting from adipose tissue loss in this region.
A higher BMI and waist circumference was observed in patients with lipoaccumulation and with mixed forms. Patients with lipoatrophy had a noticeably lower hip circumference. Patients with mixed forms had significantly higher WHR in comparison to no-LS and atrophy subgroups. The relation between dystrophic changes and anthropometric measurements was studied by Thiebaut et al. Among patients receiving cART, the prevalence of lipoatrophy grew with age and was higher in males and in patients with BMI ≤ 25. Lipoaccumulation was correlated to higher BMI and WHR; no significant relationship between lipoaccumulation and age has been discovered. The percentage of mixed forms was correlated to older age and higher WHR [26] . However, Alencastro et al. observed a different correlation between dystrophic changes and age or BMI. In their research, patients on antiretroviral therapy were older and had significantly higher BMI. Lipodystrophy and lipohypertrophy were correlated to age and BMI, whereas lipoatrophy was only correlated to BMI, without any significant influence of age [6] . Mercie et al. observed significantly older age of patients diagnosed with LS and noticeably lower BMI and CD4+ T-lymphocyte count in comparison with cART-using patients with no LS [25] . In the majority of findings, LS features are found in patients treated with antiretroviral therapy [6, 7] .
One of the main inclusion criteria for the present study was antiretroviral treatment. Its significant influence was observed especially in the subgroup of patients with severe LS. The influence of both total and cumulative time of cART on LS types and severity has been discovered. Cumulative protease inhibitors treatment was related to LS severity, but not to LS types. NRTIs medications were correlated to LS development. Cumulative time of NRTIs treatment had influence on severity of lipodystrophy and occurrence of mixed forms. The influence of time of cART on LS and its relationship with various types of lipodystrophy have been observed in numerous clinical studies [1, 7, 11, 18, 26, 27] .
However, Thiebaut et al. did not observe a significant relationship between LS and particular antiretroviral medications, except for the influence of time on cART on LS types and severity of symptoms [26] .
In many clinical studies, the influence of various classes of antiretroviral drugs and of specific antiretroviral drugs on LS in HIV-infected patients was observed. Since the introduction of antiretroviral treatment, PIs has been the first class whose side effects have been described as lipodystrophy syndrome. The influence of this class of medications, specific drugs and time of PI treatment on LS development and severity have been widely described [1, 2, 6, 11, 14, 27] .
In one of the first LS studies in 1999, Carr et al., after an over twenty-month long observation, discovered fat distribution disorders in PI-treated patients in comparison to HIV-infected, untreated patients [14] . PIs were closely associated with visceral adipose tissue growth and adverse changes in patients' metabolic profile. Since LS was also observed in patients never treated with PIs, further studies proved the negative influence of other classes of antiret- [7, 8, 11, 31] . Peripheral lipo atrophy is mostly associated with some NRTIs [5, 8, 11, 34] . Mallal et al. also found independent influence of NRTIs on LS; moreover, they discovered a correlation between the time of NRTIs treatment, the use of two different medications of this class and the increased risk of lipoatrophy. In their study of an Australian cohort of HIV-infected patients, evident influence of PIs on faster development of NRTI-induced atrophic changes, even in comparison to treatment with two different NRTI drugs, without PI, was observed. They discovered a slow development of lipoatrophy in NRTI-treated patients and progression of atrophic changes when combination therapy of NRTIs and PIs was used [11] . The influence of cART on LS prevalence was also studied by van der Valk et al. In their research, LS was more frequently diagnosed in patients on PIs and NRTIs treatment than in patients on PIs treatment alone [7] . In the present study, more severe LS and mixed forms were observed in patients with a significantly longer documented time of HIV infection. These patients were also older. These observations are consistent with most publications. The correlation between the time of HIV infection, its severity, patients' age and prevalence and severity of dystrophic changes is undisputable [6, 18, 27] . Mercie et al. discovered a visibly lower CD4+ T-lymphocyte count in a group of significantly older patients with LS than in a no-LS group [25] . In the study of 1240 patients, Alencastro et al. observed a correlation between LS and cART treatment with longer time since HIV diagnosis, older age and CD4+ T-lymphocyte count below 350 cells/µl [6] . But we did not find any significant correlation between CD4 Tcell count (nadir and present) and LS severity, probably because of the low number of patients. The lipid profile of the study group differed significantly from the profile of the control group. In the study group, total cholesterol, LDL and HDL levels were significantly lower, and triglyceride concentration was significantly higher. In comparison with the control group, the LDL cholesterol level was noticeably lower and TG concentration was significantly higher in patients with severe lipodystrophy (LS2). The vast majority of authors describing lipid dysfunction in HIV-infected patients also observe hypertriglyceridemia [1, 25, 26, 30, [35] [36] [37] . Mercie et al. also discovered a significantly higher TG concentration in LS patients than in no-LS subgroup [25] . Moreover, Hsue et al. observed a relationship between a high TG concentration and PI treatment [38] . Another metabolic dysfunction frequently observed in HIV-infected patients is a higher total cholesterol level, contrary to the findings of this study [25, 26, 30] .
Mercie et al. confirmed the relation between a high TC level and LS diagnosis [25] . Hsue et al. did not observe significant differences in TC levels between HIV-patients and healthy controls. They have, however, discovered a noticeably lower HDL level in comparison to the control group, which was also observed in other studies and in the research presented here [25, 38] . Mercie et al. demonstrated high total cholesterol and LDL levels, apart from the low HDL level, which is interpreted as a risk factor for atherosclerosis and cardiovascular diseases, especially in patients with LS [25] .
Conclusions
Lipodystrophy syndrome is still observed in the vast majority of HIV-positive patients receiving antiretroviral therapy, especially those older and with longer time of cumulative NRTI and PI treatment. Smoking is an independent risk factor of the severity of adipose tissue redistribution. A great concern is needed to evaluate body composition and risk factors for metabolic changes to prevent their progression and healthy consequences.
